论文部分内容阅读
目的本组旨在观察ACS治疗过程中3联抗血小板疗效与出血风险评估。方法 262个ACS病人随机分为观察组(3联抗血小板组)和对照组(2联抗血小板组),两组间年龄,性别,发病到医院的时间无明显差异,观察24小时和一周病人出血情况,出血程度判断标准分为严重出血,中度出血和轻微出血,终点事件为死亡。结果 24小时和一周两组间终点事件发生率观察组显著低于对照组(P<0.05),严重出血和中度出血发生率两组间无显著差异(P>0.05),轻度出血发生率观察组显著高于对照组(P<0.05)。结论 3联抗血小板治疗ACS是安全可靠的,对于高龄(超过70岁),女性,肾功能不全的病人替罗非班应适当减量。
Purpose This group was designed to evaluate the efficacy and bleeding risk assessment of triple antiplatelet therapy in ACS. Methods A total of 262 patients with ACS were randomly divided into observation group (3-antiplatelet group) and control group (2-antiplatelet group). There was no significant difference between the two groups in age, sex and time to hospital. The patients in 24 hours and one week Bleeding, bleeding to determine the standard is divided into severe bleeding, moderate bleeding and mild bleeding, the end point of death. Results The incidence of end-point events between the two groups at 24 hours and one week was significantly lower than that in the control group (P <0.05). There was no significant difference between the two groups in incidence of severe bleeding and moderate bleeding (P> 0.05) The observation group was significantly higher than the control group (P <0.05). Conclusions 3 anti-platelet therapy for ACS is safe and reliable, and should be appropriately reduced in patients with advanced age (over 70 years), women with renal insufficiency.